By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 159.88 |
Change Today | $ 4.63 |
% Change | 2.98 % |
52 Week High | $191.56 |
52 Week Low | $118.84 |
Volume | 2,878,796 |
Shares Issued | 145.80m |
Market Cap | $23,310m |
RiskGrade | 259 |
Strong Buy | 8 |
Buy | 5 |
Neutral | 21 |
Sell | 0 |
Strong Sell | 0 |
Total | 34 |
Time | Volume / Share Price |
16:00 | 237,153 @ $159.88 |
15:59 | 100 @ $159.90 |
15:59 | 1,474 @ $159.90 |
15:59 | 100 @ $159.90 |
15:59 | 100 @ $159.94 |
You are here: research